This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study., Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco.2017.35.15_suppl.5030.
You can read the full text:
The following have contributed to this page
